Phosphodiesterase-5 inhibitors (PDE-5 inhibitors) for erection problems

References

Citations

1. Lue TF, Broderick GA (2007). Evaluation and nonsurgical management of erectile dysfunction and premature ejaculation. In AJ Wein, ed., Campbell-Walsh Urology, 9th ed., vol. 1, pp. 750–787. Philadelphia: Saunders Elsevier.

2. Porst H, et al. (2003). Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial. Urology, 62(1): 121–125.

3. Seftel AD, et al. (2004). Erectile dysfunction: Etiology, evaluation, and treatment options. Medical Clinics of North America, 88(2): 387–416.

4. Cheitlin MD, et al. (1999). Use of sildenafil (Viagra) in patients with cardiovascular disease. ACC/AHA expert consensus document. Circulation, 99(1): 168–177.

5. Shakir SAW, et al. (2001). Cardiovascular events in users of sildenafil: Results from first phase of prescription monitoring in England. BMJ, 322(7287): 651–652.

6. Arruda-Olson AM, et al. (2002). Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA, 287(6): 719–725.

7. Webster LJ, et al. (2004). Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure. Archives of Internal Medicine, 164(5): 514–520.

Author:	Monica Rhodes	Last Updated: May 21, 2008
Medical Review:	E. Gregory Thompson, MD - Internal Medicine Christopher G. Wood, MD, FACS - Urology/Oncology
© 1995-2009 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.